Nexvax2 Proven Effective for Coeliac Disease

The study demonstrated the effect of weekly injections of Nexvax2 over three weeks, in coeliac patients on a strict gluten-free diet.

According to a study conducted in Melbourne in Australia, the Phase I clinical trial of Nexvax2 vaccine has shown positive results for the treatment of coeliac disease, an autoimmune condition caused by a reaction to the gluten found in wheat, rye and barley.

Immune cells react to gluten and trigger a response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.

The study demonstrated the effect of weekly injections of Nexvax2 over three weeks, in coeliac patients on a strict gluten-free diet. The results indicate that the vaccine desensitised patients to the three peptides in gluten that are regarded as toxic to those with the disease.

Dr